

Corvidane is developing Corvida™ to treat Atherosclerosis and Nonalcoholic Steatohepatitis by using novel mechanisms of action inspired by industrial lipid management techniques.

Corvida™ improves lipid metabolism to address the chemistry and cellular processes involved with atherosclerotic plaque formation, insulin sensitivity, fat accumulation, inflammation and fibrosis.



### **Corvida™ for Atherosclerosis**

*In development to be a Best-in-Class, orally administered adjunct to lipid management therapies (Statins/PCSK9) to treat Atherosclerosis.*



Atherosclerosis – The build up of fats, cholesterol and cellular waste in arterial walls. Atherosclerotic plaques are a major factor in Heart Attacks and Stroke, the leading global causes of death. Approximately 50% of people with “normal cholesterol” have some degree of atherosclerosis. In the US alone approximately 40 million people use lipid regulating drugs annually accounting for 250 million monthly prescriptions.



### **Corvida™ for NASH**

*In development to be a Best-in-Class, orally administered adjunct to Type2 Diabetes management to treat NAFLD and NASH (Stage F2 through Stage F3 Fibrosis) with no worsening of Fibrosis*

NASH – A severe form of NAFLD, which is an accumulation of excess fat in the liver and affects between 30% - 40% of U.S. adults. NASH affects 3% - 12% of American adults and 60% - 80% of those with Type 2 Diabetes. NASH is associated with cardiovascular-related mortality, cirrhosis and liver cancer and is expected to be the leading cause of liver transplants in 2020.

### **Business Plan**

*Corvidane will sell or license Corvida™ to one or more larger pharmaceutical companies. Corvida™ is targeting two very large and lucrative disease states with no effective therapeutics.*